Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Sell
36
SYNB Quote, Financials, Valuation and Earnings
Last price:
$29.90
Seasonality move
:
5.61%
Day range:
$29.90 - $29.99
52-week range:
$28.24 - $33.23
Dividend yield:
0.71%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.1K
Avg. volume:
--
1-year change:
3.01%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
THW
Tekla World Healthcare Fund
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
$29.99 | -- | -- | -- | $0.21 | 0.71% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$51.91 | -- | -- | -- | $0.33 | 5.43% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$22.70 | -- | -- | -- | $0.36 | 0% | -- |
|
THW
Tekla World Healthcare Fund
|
$11.38 | -- | -- | -- | $0.12 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | 1.093 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.988 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
|
THW
Tekla World Healthcare Fund
|
-- | 0.973 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
THW
Tekla World Healthcare Fund
|
-- | -- | -- | -- | -- | -- |
Putnam BioRevolution ETF vs. Competitors
-
Which has Higher Returns SYNB or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About SYNB or JDOC?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Putnam BioRevolution ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is SYNB or JDOC More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or JDOC?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.71%. JPMorgan Healthcare Leaders ETF offers a yield of 5.43% to investors and pays a quarterly dividend of $0.33 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or JDOC?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns SYNB or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About SYNB or THNR?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Putnam BioRevolution ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is SYNB or THNR More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or THNR?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.71%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.36 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or THNR?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
-
Which has Higher Returns SYNB or THW?
Tekla World Healthcare Fund has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Tekla World Healthcare Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- THWTekla World Healthcare Fund-- -- -- -
What do Analysts Say About SYNB or THW?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tekla World Healthcare Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Tekla World Healthcare Fund, analysts believe Putnam BioRevolution ETF is more attractive than Tekla World Healthcare Fund.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 THWTekla World Healthcare Fund0 0 0 -
Is SYNB or THW More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tekla World Healthcare Fund has a beta of 0.940, suggesting its less volatile than the S&P 500 by 5.986%.
-
Which is a Better Dividend Stock SYNB or THW?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.71%. Tekla World Healthcare Fund offers a yield of 0% to investors and pays a quarterly dividend of $0.12 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Tekla World Healthcare Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or THW?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Tekla World Healthcare Fund quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Tekla World Healthcare Fund's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Tekla World Healthcare Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Tekla World Healthcare Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- THWTekla World Healthcare Fund-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Where Will Cisco Systems Stock Be in 10 Years?
Cisco Systems, Inc. (NASDAQ:CSCO) has enjoyed its position as a…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 9
IonQ [IONQ] is down 38.82% over the past day.
Sell
40
QMCO alert for Jan 9
Quantum [QMCO] is down 30.08% over the past day.
Sell
47
MATW alert for Jan 9
Matthews International [MATW] is up 14.21% over the past day.
